Raymond Turner, MD
Neurology · Washington, DCNPI 1801977939
Payments from drug & device makers
Across 535 payments — averaging $31,064 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$8.5M
- Eisai Inc.$2.3M
- Biogen$1.9M
- Genentech, Inc.$1.6M
- Novartis$880K
- GSK$620K
- plus $836K from 13 others
Across 10 payments — averaging $28,078 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$278K
- Sage Therapeutics, LLC$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 53 | $8,454,186 |
| Eisai Inc. | 167 | $2,329,247 |
| Biogen | 32 | $1,896,414 |
| Genentech, Inc. | 71 | $1,602,937 |
| Novartis | 9 | $880,107 |
| GSK | 19 | $620,443 |
| E.r. Squibb & Sons, L.L.C. | 6 | $304,727 |
| Janssen Research & Development, LLC | 37 | $216,238 |
| Lilly USA, LLC | 109 | $103,899 |
| Sage Therapeutics, LLC | 4 | $91,553 |
| UCB SA | 2 | $60,940 |
| AbbVie | 11 | $38,951 |
| Acadia Pharmaceuticals Inc | 5 | $12,492 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $3,705 |
| Merck | 3 | $2,597 |
| F. Hoffmann-la Roche AG | 2 | $160 |
| Life Molecular Imaging Ltd | 2 | $157 |
| Baxter Healthcare | 1 | $131 |
| Genentech USA, Inc. | 1 | $92 |
How this compares
$16,618,974 in reported general payments places this provider in the 95th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Washington
- Faria AmjadWashington$4M
- Fernando PaganWashington$3.7M
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2.9M
- Brian BarryWashington$1.5M
- Benjamin OsborneWashington$1.5M
- Jessica AilaniWashington$1.5M
- Yasar Torres-YaghiWashington$1M
- Carlo TornatoreWashington$870K
- Nicholas StreicherWashington$691K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.